Logo

GC Publishes the Results of GC5107 in P-III Trial for the Treatment of Primary Immunodeficiency in Frontiers in Immunology

Share this

GC Publishes the Results of GC5107 in P-III Trial for the Treatment of Primary Immunodeficiency in Frontiers in Immunology

Shots:

  • The P-III trial evaluates the efficacy and safety of GC5107 (IV- every 21 or 28 days for 12 mos.) in 49 patients aged 3-70yrs. with PI. The trial was conducted at 17 study sites (10 in the US & 7 in Canada)
  • The trial met its1EP & 2EPs i.e.- <1 aSBI occurred among the patients during 1yr.- <40% showed temporally associated AEs within 72hrs. after infusion- >98% of the infusions were completed without discontinuation. GC5107 (10% IgG formulation) is safe- effective- and well-tolerated in adolescent and adult patients
  • In Feb’21- the company had submitted a BLA to the US FDA based on the clinical trial results. The anticipated PDUFA date for FDA’s decision on the application is Feb’22

  | Ref: Businesswire | Image: Linkedin

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions